All > Acute Myeloid Leukemia > Mds

Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Acute Myeloid Leukemia+3 MoreHematopoietic Cell Transplantation - Procedure
Eligibility
18 - 75
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing how well cytarabine, idarubicin, and daunorubicin work with or without pembrolizumab to treat patients with newly-diagnosed acute myeloid leukemia.

Eligible Conditions
  • Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
  • Therapy-Related Acute Myeloid Leukemia
  • Acute Myeloid Leukemia (AML) arising from Myelodysplastic Syndrome (MDS)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Allogeneic Hematopoietic Stem Cell Transplantation
1
Allogeneic Hematopoietic Stem Cell Transplantation
1
Hematopoietic Cell Transplantation

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: From randomization to failure to achieve CR/CRi, relapse or death from any cause, assessed up to 5 years

At day 14
MRD negativity
At end of consolidation
Rate of MRD-negative CR
At time of count recovery after first cycle of consolidation therapy with chemotherapy and pembrolizumab
Percentage of patients with minimal residual disease - complete response (MRD-CR)
At time of count recovery after induction therapy with chemotherapy and pembrolizumab
Assess the rate of CR/incomplete count recovery (CRi)
Year 3
Immune cell subsets
PD-1 and PD-L1 expression
Protein signatures
Baseline
Genomic deoxyribonucleic acid (DNA) of tumor cells
Year 5
Duration of response (DOR)
Year 5
Relapse-free survival (RFS)
Year 5
Event-free survival
Day 35
Incidence of adverse events
Up to end of consolidation
MRD assessment
MRD detection
Year 3
Ribonucleic acid (RNA) integrity of formalin fixed paraffin-embedded RNA
T cell receptor (TCR) sequencing

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Allogeneic Hematopoietic Stem Cell Transplantation
1
Allogeneic Hematopoietic Stem Cell Transplantation
1
Hematopoietic Cell Transplantation

Side Effects for

Treatment (Enzyme Inhibitor, Transplant, GVHD Prophylaxis)
48%Neutropenia
10%Death following disease progression post transplant
10%Hyperbilirubinemia
10%Thrombocytopenia
10%Hypoxia
5%Death: Sepsis/Renal failure/ with history of GVHD
5%Death following progression of GVHD
5%Renal failure
5%Hypotension
5%Minimal hydronephosis
5%Cardiac Arrhythmia and Seizure
5%Perforated sigmoid diverticulitis
5%Acute Pulmonary Embolism
5%Neurotoxicity
5%Typhlitis & Bowel Perforation
5%Severe abnormal pain due to gut GVH
5%Tumor lysis syndrome
5%Increased creatinine
5%Cholecystectomy
This histogram enumerates side effects from a completed 2010 Phase 2 trial (NCT00060424) in the Treatment (Enzyme Inhibitor, Transplant, GVHD Prophylaxis) ARM group. Side effects include: Neutropenia with 48%, Death following disease progression post transplant with 10%, Hyperbilirubinemia with 10%, Thrombocytopenia with 10%, Hypoxia with 10%.

Trial Design

2 Treatment Groups

Arm II (cytarabine, idarubicin, daunorubicin, HSCT)
1 of 2
Arm I (cytarabine, idarubicin, daunorubicin, HSCT)
1 of 2

Active Control

Experimental Treatment

124 Total Participants · 2 Treatment Groups

Primary Treatment: Hematopoietic Cell Transplantation · No Placebo Group · Phase 2

Arm I (cytarabine, idarubicin, daunorubicin, HSCT)Experimental Group · 5 Interventions: Cytarabine, Daunorubicin Hydrochloride, Idarubicin Hydrochloride, Hematopoietic Cell Transplantation, Pembrolizumab · Intervention Types: Drug, Drug, Drug, Procedure, Biological
Arm II (cytarabine, idarubicin, daunorubicin, HSCT)ActiveComparator Group · 4 Interventions: Cytarabine, Daunorubicin Hydrochloride, Idarubicin Hydrochloride, Hematopoietic Cell Transplantation · Intervention Types: Drug, Drug, Drug, Procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cytarabine
FDA approved
Daunorubicin
FDA approved
Idarubicin
FDA approved
Hematopoietic Cell Transplantation
2006
Completed Phase 2
~270
Pembrolizumab
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from randomization to failure to achieve cr/cri, relapse or death from any cause, assessed up to 5 years

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,098 Previous Clinical Trials
41,145,653 Total Patients Enrolled
Amer M ZeidanPrincipal InvestigatorYale University Cancer Center LAO
2 Previous Clinical Trials
103 Total Patients Enrolled

Eligibility Criteria

Age 18 - 75 · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients with prior use of HMA, lenalidomide, erythropoiesis-stimulating agents (ESAs), and growth factors are allowed if used to treat prior MDS.
Children aged 6 to 17 years with a confirmed diagnosis of unresectable or metastatic solid tumors are eligible for this study.
You have a performance status of -2.
You are eligible to receive intensive \"7+3\" induction chemotherapy as judged by the treating physician.
Creatinine =< 1.5 x ULN OR measured or calculated CrCl > 60 mL/min for patient with creatinine levels > 1.
Creatinine clearance (CrCl) should be calculated per institutional standard.
GFR can be used in place of CrCl or Cr.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top